Mimedx Message Board


MiMedx knows they sell unsafe products

3 months ago

Well, well, well. MiMedx has always assured the public that their tissue grafts are safe with no complications for patients. Now a report from Bloomberg tells a different story:

Top officials at the company are aware of at least 50 instances of patient complications that followed treatments with MiMedx’s skin grafts or injections, according to people familiar with the matter and documentation reviewed by Bloomberg News. As of early last year, the company had reported four incidents to regulator…

Parker Petit Please Resign

3 months ago

“We thank our shareholders for their strong support and participation. The overwhelming support the company has received throughout this process is an unmistakable statement by MiMedx’s shareholders that it is time to move beyond the Pete Petit era and to focus again on MiMedx’s business and growth opportunities. With such strong support for our new CEO and board members, we are hopeful that Mr. Petit will stand down from further actions that could distract the company from its mission to …

MiMedx Releases New Corporate Presentation Prior to Annual Meeting

3 months ago



Parker is still trying to getelected to the MiMedx Board so the company had to put out a presentation why that wouldn't be a good idea.


FDA Grants Fast Track Designation for FARXIGA in Heart Failure

13 hours ago

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

MiMedx Spying to Discredit Whistleblowers

3 months ago

Parker truly has no limits! We all knew but now it has been confirmed.

After uncovering that former executives had spied on employees to discredit whistleblowers, MiMedx Group announced several changes to its board, including the appointment of new CEO Tim Wright, MarketWatch reports.

The MiMedx Payday Advantage

3 months ago

It is insane although reps aren't making that much anymore.

Adios MiMedx, Hello Smith & Nephew and Osiris

6 months ago

The problem Smith & Nephew will have is that customers don't trust anyone in this space any longer because of MiMedx.

Intact Vascular to Announce One-Year Data from TOBA III Clinical Trial

13 hours ago

​Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that the one-year data from its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial will be presented during the High Impact Clinical Research session of the 31st

MiMedx Account Executive Information

6 months ago

Lastly , the competition is having a field day with Mimedx all over.

Organogenesis is laughing all the way to the bank.

Osiris Lawsuit Against MiMedx

7 months ago

Is this a new lawsuit from Osiris Therapeutics claiming MiMedx owes it at least $6.4 million? Osiris is claiming deceit, trickery and unfair methods. I can’t tell if it’s part of an old lawsuit or a brand new one.

L2 Surgical, Next Health and MiMedx

7 months ago

Next Health was a shady pharmacy and they cut a deal with Rimlawi and Nicholson from Forest Park. Next Health agreed to pay the docs for prescribing drugs for their patients using Next Health pharmacies.

Both owners of Next Health have already pleaded guilty to billing private insurance plans more than $450 million and collecting $150 million in fraudulent proceeds.

More kickback schemes will be coming out in the Forest Park Medical Center trial which starts today.

National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

14 hours ago

​Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that the National Lipid Association (NLA) has issued a position statement recognizing the cardiovascular risk-lowering effects of icosapent ethyl based on the landmark REDUCE-IT cardiovascular outcomes study.

MiMedx Layoffs and Restructuring

7 months ago

For those who are fooled by David Coles, do not get sucked in to his vortex. He could be a great guy but you need to realize that he is a restructuring specialist and not here for the long term. He is looking at the business to figure out what, if anything can be salvaged. The board would have hired a real CEO if they could have found one but no one wants it. Believing he is excited for the future is like believing in Santa. The next round of layoffs will be when the doors close and the assets w…

2019 Sales Meeting

7 months ago

For those who are fooled by David Coles, do not get sucked in to his vortex. He could be a great guy but you need to realize that he is a restructuring specialist and not here for the long term. He is looking at the business to figure out what, if anything can be salvaged. The board would have hired a real CEO if they could have found one but no one wants it. Believing he is excited for the future is like believing in Santa. The next round of layoffs will be when the doors close and the assets w…

Save Yourself and Become the Whistleblower at Mimedx

9 months ago

I hope the whistleblower makes a bunch of money and they help send Petit to jail for the rest of his life.

Celgene Announces Phase 3 QUAZAR AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints

3 days ago

Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML)

What's it like being a sales rep at MiMedx?

10 months ago

now that the stick has been delisted

1.Institutional investors will dry up

2. Internal spending will increase for lawyers and audits

3. Cash flow and profits will decrease

4. Consultant surgeon payments will dry up

5. Funding for new studies and products will decrease

6. Management and Sales reps will leave .

Loading...